Literature DB >> 28692133

New insights into enterocin CRL35: mechanism of action and immunity revealed by heterologous expression in Escherichia coli.

Daniela E Barraza1, Natalia S Ríos Colombo1, Adriana E Galván1, Leonardo Acuña1, Carlos J Minahk1, Augusto Bellomio1, Miriam C Chalón1.   

Abstract

The role of the class IIa bacteriocin membrane receptor protein remains unclear, and the following two different mechanisms have been proposed: the bacteriocin could interact with the receptor changing it to an open conformation or the receptor might act as an anchor allowing subsequent bacteriocin insertion and membrane disruption. Bacteriocin-producing cells synthesize an immunity protein that forms an inactive bacteriocin-receptor-immunity complex. To better understand the molecular mechanism of enterocin CRL35, the peptide was expressed as the suicidal probe EtpM-enterocin CRL35 in Escherichia coli, a naturally insensitive microorganism since it does not express the receptor. When the bacteriocin is anchored to the periplasmic face of the plasma membrane through the bitopic membrane protein, EtpM, E. coli cells depolarize and die. Moreover, co-expression of the immunity protein prevents the deleterious effect of EtpM-enterocin CRL35. The binding and anchoring of the bacteriocin to the membrane has demonstrated to be a sufficient condition for its membrane insertion. The final step of membrane disruption by EtpM-enterocin CRL35 is independent from the receptor, which means that the mannose PTS might not be involved in the pore structure. In addition, the immunity protein can protect even in the absence of the receptor.
© 2017 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28692133     DOI: 10.1111/mmi.13746

Source DB:  PubMed          Journal:  Mol Microbiol        ISSN: 0950-382X            Impact factor:   3.501


  8 in total

Review 1.  Pediocin-like bacteriocins: new perspectives on mechanism of action and immunity.

Authors:  Natalia S Ríos Colombo; Miriam C Chalón; Silvia A Navarro; Augusto Bellomio
Journal:  Curr Genet       Date:  2017-10-05       Impact factor: 3.886

Review 2.  Features and applications of Ent35-MccV hybrid bacteriocin: current state and perspectives.

Authors:  S A Navarro; L Lanza; L Acuña; A Bellomio; Miriam C Chalón
Journal:  Appl Microbiol Biotechnol       Date:  2020-05-16       Impact factor: 4.813

Review 3.  Heterologous Expression of Biopreservative Bacteriocins With a View to Low Cost Production.

Authors:  Beatriz Mesa-Pereira; Mary C Rea; Paul D Cotter; Colin Hill; R Paul Ross
Journal:  Front Microbiol       Date:  2018-07-26       Impact factor: 5.640

4.  Angicin, a novel bacteriocin of Streptococcus anginosus.

Authors:  Verena Vogel; Richard Bauer; Stefanie Mauerer; Nicole Schiffelholz; Christian Haupt; Gerd M Seibold; Marcus Fändrich; Paul Walther; Barbara Spellerberg
Journal:  Sci Rep       Date:  2021-12-21       Impact factor: 4.379

Review 5.  Enterocins: Classification, Synthesis, Antibacterial Mechanisms and Food Applications.

Authors:  Yajing Wu; Xinxin Pang; Yansha Wu; Xiayu Liu; Xinglin Zhang
Journal:  Molecules       Date:  2022-03-30       Impact factor: 4.411

6.  The bacteriocin Angicin interferes with bacterial membrane integrity through interaction with the mannose phosphotransferase system.

Authors:  Verena Vogel; Lia-Raluca Olari; Marie Jachmann; Sebastian J Reich; Michelle Häring; Ann-Kathrin Kissmann; Frank Rosenau; Christian U Riedel; Jan Münch; Barbara Spellerberg
Journal:  Front Microbiol       Date:  2022-09-06       Impact factor: 6.064

7.  Isolation and Molecular Identification of Bacteriocin-producing Enterococci with Broad Antibacterial Activity from Traditional Dairy Products in Kerman Province of Iran.

Authors:  Khodaei M; Soltani Nezhad Sh
Journal:  Korean J Food Sci Anim Resour       Date:  2018-02-28       Impact factor: 2.622

8.  BacSJ-Another Bacteriocin with Distinct Spectrum of Activity that Targets Man-PTS.

Authors:  Aleksandra Tymoszewska; Piotr Walczak; Tamara Aleksandrzak-Piekarczyk
Journal:  Int J Mol Sci       Date:  2020-10-23       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.